Efficacy and safety of abacavir plus efavirenz as a salvage regimen in HIV-infected individuals after 48 weeks.
Wasmuth
Jan-Christian
JC
Department of Internal Medicine I, University of Bonn, Bonn, Germany.
Herhaus
Christina
C
Römer
Katja
K
Salzberger
Bernd
B
Kaiser
Rolf
R
Schliefer
Kirsten
K
Voigt
Esther
E
Rockstroh
Jürgen K
JK
D000480:Alkynes; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D048588:Benzoxazines; D018791:CD4 Lymphocyte Count; D003521:Cyclopropanes; D015224:Dideoxynucleosides / Q000008:administration & dosage / Q000627:therapeutic use*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D010078:Oxazines / Q000008:administration & dosage / Q000627:therapeutic use*; D010352:Patient Dropouts / Q000706:statistics & numerical data; D012189:Retrospective Studies; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D016879:Salvage Therapy; D017211:Treatment Failure; D016896:Treatment Outcome; D019562:Viral Load; D000099227:Abacavir
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D015224:Dideoxynucleosides; D017320:HIV Protease Inhibitors; D010078:Oxazines; D018894:Reverse Transcriptase Inhibitors; D000099227:Abacavir; C098320:efavirenz